Venetoclax, a Bcl-2 inhibitor, reduced the increased tumorsphere size more efficiently in Nf2-KO S1 and NF2-KO SNU-668 cells than in control cells (Fig. 4, O and P), indicating that Bcl-2 mediates the increased cancer stemness induced by NF2 deficiency. Here, NF2 is linked to cancer.